Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that treating female hair loss should target reducing excess androgen and blocking its effects on hair follicles, with the best treatments being hormonal therapy, adrenal suppression, and topical minoxidil.

Low-dose anti-androgen drugs and certain drug combinations are effective for hirsutism, and insulin sensitizers show promise, especially for those with polycystic ovarian syndrome.

Hormonal treatments can change hair and skin in transgender people, but may not fully achieve desired results.

Most women with excessive hair growth have PCOS; treatment varies and focuses on preventing new hair, with electrolysis as the only permanent removal method.

Hirsutism in women is often due to hormone sensitivity and has significant psychological effects.

PCOS is a major cause of infertility and requires personalized treatment.

Finasteride treatment changes urine metabolomics and steroid signatures, potentially monitoring effectiveness but may cause sexual side effects.

Certain adrenal hormones can strongly stimulate oil gland growth in hamster skin, similar to male hormones.

Testosterone treatment can improve sexual function and bone density in women but may have adverse effects and requires more research on safety and guidelines.

Some alopecia treatments might help treat COVID-19, but more research is needed.

A young woman's symptoms suggested PCOS, but tests and surgery confirmed and treated a rare ovarian tumor, resolving her condition.

OCIAD2 and DCN genes affect hair growth in goats by having opposite effects on a growth signaling pathway and inhibiting each other.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.

Early diagnosis and treatment of PCOS in teenagers can help prevent more severe adult PCOS.

Personalized treatment is crucial for effectively managing benign prostatic hyperplasia (BPH).

Exercise and finasteride together improve ovary health in PCOS rats.

5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.

TMPRSS2 is crucial for COVID-19 infection and is a potential target for treatment.

The conclusion is that hair loss in women is caused by a mix of hormonal, environmental, and genetic factors, and treatments should target these various causes.

Dermal papilla cells are key for hair growth and color, influencing hair type and size, and their interaction with stem cells could help treat hair loss and color disorders.

Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.

The document concludes that hair loss is complex, affects many people, has limited treatments, and requires more research on its causes and psychological impact.

New treatments for hair loss are being developed using molecular biology.

Early treatment and weight management are important for teenagers with PCOS to reduce symptoms and long-term health risks.

Finasteride affects offspring's antioxidant enzymes in epididymis, possibly disrupting sperm maturation.

Flutamide and a new synthetic steroid affected brain and prostate chemicals and showed potential for treating androgen-related conditions and epilepsy.

Women with PCOS have a higher risk of metabolic syndrome and need lifestyle changes and treatment.

Collagen networks play a key role in hair loss and follicle miniaturization.

Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.

Biologic agents are effective for severe hidradenitis suppurativa when other treatments fail.